Spanish Series of Patients Treated With the Radionuclide Lutetium177
-
- STATUS
- Recruiting
-
- End date
- Dec 31, 2035
-
- participants needed
- 5000
-
- sponsor
- Sociedad Española de Medicina Nuclear e Imagen Molecular
Summary
This study aims to pool the clinical experience of Spanish centers treating patients with 177Lu-DOTATATE to evaluate the efficacy, tolerance, and safety of the drug in routine clinical practice and to learn about the profiles of patients and tumors treated and the results in each type of patient and tumor.
Description
Patient data will be collected from medical records after obtaining consent and retrospectively.
Details
| Condition | endocrine diseases, Islet Ce417ll Cancer, enteropathy, gastrointestinal tumors, bowel disease, neuroendocrine tumour, Bowel Dysfunction, Gastrointestinal Neoplasm, Gastric Cancer, gastrointestinal tumor, digestive diseases, Endocrine disorder, endocrinopathy, endocrine disorders, Gastropathy, Cancer/Tumors, Intestinal Cancer, Neoplasms by Histologic Type, Stomach Cancer, Neoplasms by Site, gastrointestinal disease, neuroendocrine tumors, pancreatic neoplasm, digestive disease, Intestinal Diseases, Cancer, Germ cell tumor, Neuroectodermal Tumor, Endocrine neoplasm, Pancreatic disorder, Cancer (Pediatric), Neoplasms, Nerve Tissue, Pancreatic Disorders, bowel disorders, diseases of the intestinal tract, digestive disorders, Neoplasm of unspecified nature of digestive system, gastrointestinal tract tumor, Neuroendocrine Tumor, Gastrointestinal Diseases and Disorders, GASTROINTESTINAL DISORDER, Neurectoderma, gastric tumor, endocrine neoplasia, digestive disorder, intestinal disease, Stomach Discomfort, gastrointestinal disorders, intestinal tumors, Digestive System Disease, Digestive System Neoplasms, Pancreatic Cancer, Neoplasms, Germ Cell Tumors, endocrine disease, gastric neoplasm, gastrointestinal diseases, Ewing's Family Tumors, digestive system tumor |
|---|---|
| Treatment | Lutetium [177Lu] oxodotreotide/dotatate |
| Clinical Study Identifier | NCT04949282 |
| Sponsor | Sociedad Española de Medicina Nuclear e Imagen Molecular |
| Last Modified on | 9 July 2021 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer